The Filing Desk

Enanta Pharmaceuticals

ENTA · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

ENTA · Last close · November 19, 2026
$7.98
Value Enanta Pharmaceuticals yourself

Enanta Pharmaceuticals' revenue fell 3.6% to $63 million in fiscal 2026. Its operating margin was −99.0%, up from −130.7% a year earlier. Free cash flow was −$43 million. The diluted share count rose 35.9%.

ENANTA PHARMACEUTICALS, INC Latest fiscal year ended September 30, 2026 10-K filed November 18, 2026 · 0001193125-26-466170 Updated
Revenue
$63M
3.6%
Operating margin
−99.0%
31.6 pts
Net income
−$68M
 
Free cash flow
−$43M
 
Return on equity
−94.2%
9.6 pts
Market cap
$231M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Enanta Pharmaceuticals does

Enanta Pharmaceuticals is a biotechnology company that uses its chemistry and drug discovery skills to develop small molecule drugs, mainly for viral infections and immune diseases. It had 74 full-time employees as of September 30, 2026.

Its revenue comes from royalties. It discovered glecaprevir, an antiviral protease inhibitor that is part of AbbVie's hepatitis C (HCV) treatment sold as MAVYRET in the US and MAVIRET elsewhere. AbbVie sells it, and Enanta earns royalties on those sales.

Its own programs are in two areas. In virology it is focused on respiratory syncytial virus (RSV), a common cause of lung infections in young children and older adults, with a candidate called zelicapavir, and it has a clinical-stage program for the virus that causes COVID-19. In immunology it is developing oral small molecules for type 2 inflammatory diseases such as atopic dermatitis, urticaria and asthma. Enanta has not independently developed any approved product.

Its biggest risks, as it describes them

  • It will need substantial additional funding, and may be unable to get it.
  • It has had net losses and expects more operating losses.
  • Its revenue depends on royalties on AbbVie's sales of the MAVYRET/MAVIRET HCV treatment.
  • It faces competition in HCV, RSV and the immune diseases it targets.
  • It has limited experience developing and selling drugs on its own.
From Enanta Pharmaceuticals's annual report on Form 10-K, filed November 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2019, earnings per share grew 55.8% a year and net income 61.9% a year, as new shares raised the share count by 8% and diluted each share's earnings. Enanta Pharmaceuticals then lost money in fiscal 2020, 2021, 2022, 2023, 2024, 2025 and 2026.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments249370248189194
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—−26.6x−11.1x−11.1x−4.4x
Current ratio10.4x6.7x5.2x4.2x3.8x
Quick ratio10.4x6.7x5.2x4.2x3.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Enanta Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Enanta Pharmaceuticals says to expect

  • Cash runwayEnanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 16, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Enanta Pharmaceuticals shares on the open market, and 7 insiders sold $183,168.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Dec 5, 2025Jay R. LulyPresident and CEO, DirectorSold4,743$14.23$67,493Form 4
Dec 5, 2025Yat Sun OrChief Scientific OfficerSold2,390$14.23$34,010Form 4
Dec 5, 2025Tara Lynn KiefferChief Product Strategy OfficerSold2,106$14.23$29,968Form 4
Dec 5, 2025Brendan LuuChief Business OfficerSold1,394$14.23$19,837Form 4
Dec 5, 2025Scott T. RottinghausChief Medical OfficerSold798$14.23$11,356Form 4
Dec 5, 2025Harry R. Trout IIISee RemarksSold542$14.23$7,713Form 4
Dec 5, 2025Kathleen S. CappsSee RemarksSold323$14.23$4,596Form 4
Dec 2, 2025Harry R. Trout IIISee RemarksSold380$13.96$5,305Form 4
Dec 2, 2025Kathleen S. CappsSee RemarksSold207$13.96$2,890Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score———
Rule of 40−157.6%−52.7%−71.4%
Altman Z''−0.20−2.79−3.08
Accruals ratio−8.9%−19.1%−9.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Enanta Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Enanta PharmaceuticalsFY26−3.6%−99.0%−67.9%———
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Fortress BiotechFY259.7%−111.0%—−323.7%—6Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Journey MedicalFY2510.2%−13.2%—−22.4%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue103207205122978679686563
Revenue growth16.5%101.0%−0.7%−40.3%−20.7%−11.2%−8.1%−14.6%−3.4%−3.6%
Gross profit——————————
Research and development589514213717416416413210788
Operating income258837−42−110−124−137−122−85−62
Net income187246−36−79−122−134−116−82−68
Diluted EPS (US$)0.913.482.21−1.81−3.92−5.91−6.38−5.48−3.84−2.35
Diluted shares (millions)19212120202121212129
Cash flow
Cash from operations5329717−70−85−103−79−19−43
Capital expenditure235112918130
Free cash flow5026666−71−87−112−97−32−43
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation13161920212728271914
Balance sheet at fiscal year end
Cash and short-term investments224309335387244249370248189194
Debt incl. finance leases——————————
Total assets327414490486439375462377281276
Total liabilities252027313954246248216195
Shareholders' equity3023944624563993212171296580
Margins and ratios
Gross margin——————————
Operating margin23.9%42.8%17.9%−34.0%−112.9%−143.7%−173.2%−179.9%−130.7%−99.0%
Net margin17.2%34.8%22.6%−29.5%−81.4%−141.3%−168.9%−171.6%−125.4%−108.3%
Free cash flow margin48.8%12.7%32.2%4.6%−72.9%−100.9%−141.7%−143.0%−49.2%−67.9%
Rule of 40 (growth + FCF margin)65.2%113.7%31.5%−35.7%−93.6%−112.1%−149.8%−157.6%−52.7%−71.4%
Return on capital——————————
Return on equity6.2%20.7%10.8%−7.9%−18.5%−33.8%−49.7%−67.2%−84.6%−94.2%
Return on assets5.8%19.4%10.3%−7.4%−17.1%−29.9%−31.9%−27.7%−24.9%−24.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Enanta Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Enanta Pharmaceuticals.